Chromium Picolinate Supplementation Attenuates Body Weight Gain and Increases Insulin Sensitivity in Subjects With Type 2 Diabetes
Article Figures & Tables
Figures
- Figure 1—
Study design (A) and study flow and numbers (B) for each study period.
- Figure 2—
A: Body weight changes for all subjects over the treatment period. •, placebo; □, CrPic. B: Abdominal fat distribution for all subjects over the treatment period.
, control; ▪, CrPic. *P < 0.05; **P < 0.01. Data are means± SE.
Tables
- Table 1—
Changes observed from baseline for metabolic and phenotypic parameters
Period 1 Period 2 Sulfonylurea + placebo Sulfonylurea + placebo Sulfonylurea + CrPic Glycemia Fasting glucose (mg/dl) −19.98 ± 5.33 0.0009 −11.33 ± 8.03 NS −31.00 ± 7.37 0.0002 GHb (%) −1.07 ± 0.26 0.0006 −0.44 ± 0.43 NS −1.16 ± 0.38 0.0049 Glucose AUC −7,794 ± 1238 0.0001 −6,454 ± 2289 0.0092 −11,131 ± 2108 0.0001 Glucose AUC-B −2,531 ± 873 0.008 −2,501 ± 1412 NS −3,981 ± 1269 0.0043 Insulin Glucose disposal (mg/min per fat-free mass) 21.9 ± 11.8 NS 15.9 ± 18.5 NS 28.9 ± 11.3 0.0209 Insulin AUC 3,460 ± 522 0.0001 2,969 ± 1102 0.013 3,498 ± 985 0.0016 Insulin AUC-B 2,604 ± 518 0.0001 1,618 ± 754 0.042 2,022 ± 657 0.0052 Fasting C-peptide (ng/ml) −0.007 ± 0.030 NS 0.136 ± 0.111 NS 0.173 ± 0.093 NS Indirect calorimetry Respiratory quotient 0.005 ± 0.006 NS −0.006 ± 0.010 NS 0.005 ± 0.009 NS REE 53.74 ± 28.1 NS 59.43 ± 40.3 NS 29.14 ± 36.4 NS DEXA scans % fat 0.22 ± 0.44 NS 1.17 ± 0.31 0.0008 0.12 ± 0.35 NS Fat-free mass 0.59 ± 0.40 NS 0.68 ± 0.46 NS 1.07 ± 0.44 0.0227 Lipids/adipocytokines FFAs (mmol/l) −0.12 ± 0.05 0.018 −0.12 ± 0.05 0.028 −0.20 ± 0.05 0.0007 Triglycerides (mg/dl) 11.43 ± 13.04 NS 3.68 ± 18.86 NS 30.32 ± 18.19 NS Log (Triglycerides) 0.09 ± 0.07 NS 0.06 ± 0.090 NS 0.13 ± 0.087 NS Adiponectin (mg/ml) 2.06 ± 0.60 0.002 0.74 ± 0.75 NS 0.93 ± 0.702 NS -
Data are means ± SE or P values. REE, resting energy expenditure.
-
In this Issue
August 2006, 29(8)
Chromium Picolinate Supplementation Attenuates Body Weight Gain and Increases Insulin Sensitivity in Subjects With Type 2 Diabetes
